English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

ABS (Ankaferd Hemostat) has emerged as a novel haemostatic agent of plant origin. Its ability to interact with entire proteins including cell surface receptors and/or blood proteins plus tissue proteins revealed novel functions of ABS to biologic systems especially tumor associated transcription factors. Thus, in our study, we aimed to investigate the effects of ABS on lymphoid neoplastic cells in vitro. We showed that Ankaferd treated B-CLL cells (at doses 0.5, 1 and 2 μg/mL) ceased to inflate and more than 50% of tumor cells were died compared to 0.1 and 0.25 μg/mL doses. Additionally, transformation of B-CLL cells to the blastic aggressive lymphoid forms was prevented by addition of Ankaferd to culture medium. The results have given the clues of anti-neoplastic effects at higher doses (>0.5 μg/mL) and induction of cellular differentiation at lower doses (<0.5 μg/mL) and proposed future advances in treatment of neoplastic bleedings.

Acute in Vitro effects of ABS (Ankaferd Hemostat) on the Lymphoid Neoplastic Cells (B-CLL and RAJI Tumor Cell Lines)